Bristol-Myers Squibb Company has purchased an exclusive option to acquire F-star Alpha Ltd, a Cambridge, UK-based company which has a preclinical drug candidate targeting HER2-positive tumours including those that are refractory to trastuzumab and pertuzumab.
